For the roughly 39 million people living with HIV globally, the prospect of a long-acting antibody-based therapy — one that could reduce or even replace daily antiretroviral pill burdens — represents a meaningful shift in disease management. New preclinical data on BNT351 move that possibility measurably closer to clinical reality.
BNT351 is an engineered variant of the parent broadly neutralizing antibody (bNAb) 1-18, modified with so-called LS mutations in the antibody's Fc region. These point mutations dramatically increase binding affinity to the neonatal Fc receptor (FcRn) — the recycling mechanism responsible for extending immunoglobulin half-life in circulation — by approximately 20-fold compared to the unmodified antibody. The practical consequence is striking: half-lives of 10–14 days in transgenic mice and 18 days in non-human primates, projecting to roughly 50 days in humans. Across a 119-strain multiclade neutralization panel, BNT351 preserved the exceptional potency and breadth of its parent. In humanized CD34+ NSG mice with active HIV-1 infection, it fully suppressed viremia without driving the emergence of resistant viral variants. An off-target binding screen against approximately 6,500 human proteins returned no safety signals.
LS mutation engineering is an established half-life extension strategy — applied previously to antibodies in respiratory syncytial virus and malaria contexts — but its application here to an HIV bNAb with this level of neutralization breadth is notable. The 1-18 lineage already stood out in the bNAb landscape for covering diverse HIV-1 clades, including the globally prevalent clade C. The absence of resistance emergence in the mouse model is encouraging, though humanized mouse viremia models are imperfect surrogates for chronic human infection dynamics. This remains entirely preclinical outside the announced Phase 1 trial (NCT07392372), and translation from NHP pharmacokinetics to human outcomes carries inherent uncertainty. Still, the combination of extended half-life, broad neutralization, and a clean safety profile positions BNT351 as one of the more technically complete bNAb candidates to enter human trials — an incrementally important but genuinely meaningful step forward for long-acting HIV prevention and treatment.